-- Robert Preidt
MONDAY, Oct. 25 (HealthDay News) -- Patients who receive
radiation before surgery for rectal cancer are about 50 percent
less likely to experience a return of their cancer, a new Dutch
study has found.
Local recurrence -- the return of cancer to the original tumor
site and surrounding area -- is a major problem in the treatment of
rectal cancer patients, explained the researchers from Leiden
University Medical Center in the Netherlands.
This recurrence often occurs in lymph nodes in the mesorectum,
which is fatty tissue near the rectum. That's why many patients
undergo a surgical procedure called total mesorectal excision
(TME), which removes the entire mesorectum and lymph nodes, the
study authors explained.
The researchers found that radiation treatment before surgery
cuts the risk of cancer recurrence after 10 years by about
The study included more than 1,800 rectal cancer patients
scheduled for TME. They were randomly selected to receive
short-term radiation before surgery or surgery alone. Ten years
after treatment, the risk of local cancer recurrence was 6 percent
in the radiation/surgery group and 11 percent in the surgery-alone
group, the investigators reported.
The findings are to be presented Nov. 1 at the American Society
for Radiation Oncology (ASTRO) annual meeting, in San Diego.
"We believe that this short course of radiation will open a new window of opportunities in the treatment of rectal cancer," study author and radiation oncologist Dr. Corrie Marijnen said in an ASTRO news release.
She added that the "study suggests that tumors in the middle
rectum and stage III rectal cancer patients will most greatly
benefit from receiving radiation before surgery."
"TME is an important advance in the surgical management of rectal carcinoma. Unfortunately, the complexity of the anatomy involved is such that even with expert surgery, there are still patients who will experience recurrence of their cancer in the pelvic region, compromising their survival and markedly impairing the quality of their life," explained Dr. Bernadine Donahue, vice chair and clinical director of radiation oncology at Maimonides Cancer Center in New York City.
"The large Dutch experience has helped identify which subsets of patients will benefit from preoperative radiation therapy as a means of decreasing the risk of local recurrence. In the Dutch trial, an intense short course of radiation therapy was delivered prior to surgery. This clearly improved tumor control and that is good news," Donahue noted. "However, most North American facilities deliver [an] equivalent amount of radiation packaged as smaller amounts daily over a longer period of time to decrease the likelihood of long-term toxicity. It remains to be seen what the long-term side effects of the Dutch approach will be."
Experts note that studies presented at scientific meetings do
not face the same peer-review scrutiny as those published in
The U.S. National Cancer Institute has more about
treatment of rectal cancer.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.